Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial

Journal of the National Cancer Institute

Volumn 109, Issue 5, 2017, Pages

  Shieh, Yiwey ^a   Eklund, Martin ^b   Madlensky, Lisa ^c   Sawyer, Sarah D ^a   Thompson, Carlie K ^a   Stover Fiscalini, Allison ^a   Ziv, Elad ^a   Van't Veer, Laura J ^a   Esserman, Laura J ^a   Tice, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNUAL MAMMOGRAPHY; BIENNIAL MAMMOGRAPHY; BREAST CANCER; BREAST DENSITY; CANCER SCREENING; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PENETRANCE; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; BREAST TUMOR; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; GENETICS; GENOTYPE; PRACTICE GUIDELINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; TIME FACTOR;

AGE FACTORS; BREAST DENSITY; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; PENETRANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRACTICE GUIDELINES AS TOPIC; PRAGMATIC CLINICAL TRIALS AS TOPIC; PRECISION MEDICINE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 85017486792     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw290     Document Type: Review

References (79)

1. Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727-737, w237-w242.
2. Mainiero MB, Lourenco A, Mahoney MC, et al. ACR appropriateness criteria breast cancer screening. J Am Coll Radiol. 2013;10(1):11-14.
3. Practice bulletin no. 122: Breast cancer screening. Obstet Gynecol. 2011;118(2 Pt 1):372-382.
4. Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314(15):1599-1614.
5. Fedewa SA, de Moor JS, Ward EM, et al. Mammography use and physician recommendation after the 2009 U.S. Preventive Services Task Force breast cancer screening recommendations. Am J Prev Med. 2016;50(5):e123-e131.
6. Haas JS, Sprague BL, Klabunde CN, et al. Provider attitudes and screening practices following changes in breast and cervical cancer screening guidelines. J Gen Intern Med. 2016;31(1):52-59.
7. Siu AL. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Int Med. 2016;164(4):279-296.
8. Schousboe JT, Kerlikowske K, Loh A, et al. Personalizing mammography by breast density and other risk factors for breast cancer: Analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155(1):10-20.
9. Shieh Y, Eklund M, Sawaya GF, et al. Population-based screening for cancer: Hope and hype. Nat Rev Clin Oncol. 2016;13(9):550-565.
10. Pashayan N, Duffy SW, Chowdhury S, et al. Polygenic susceptibility to prostate and breast cancer: Implications for personalised screening. Br J Cancer. 2011;104(10):1656-1663.
11. Feig SA. Personalized screening for breast cancer: A wolf in sheep's clothing? Am J Roentgenol. 2015;205(6):1365-1371.
12. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
13. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999; 91(18):1541-1548.
14. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006;98(17):1215-1226.
15. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358-366.
16. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695-1705.
17. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111-1130.
18. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40(11):807-814.
19. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study. Am J Epidemiol. 2000;152(10):950-964.
20. Colditz GA, Rosner BA, Chen WY, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3): 218-228.
21. Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: Development and validation of a new predictive model. Ann Intern Med. 2008;148(5): 337-347.
22. Tice JA, Miglioretti DL, Li CS, et al. Breast density and benign breast disease: Risk assessment to identify women at high risk of breast cancer. J Clin Oncol. 2015;33(28):3137-3143.
23. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101(6):384-398.
24. Nelson HD, Smith ME, Griffin JC, et al. Use of medications to reduce risk for primary breast cancer: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158(8):604-614.
25. Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89(3):227-238.
26. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
27. Boughey JC, Hartmann LC, Anderson SS, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol. 2010;28(22): 3591-3596.
28. Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat. 2012;132(2):365-377.
29. Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373-380.
30. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4): 353-361, 361e1-361e2.
31. Dite GS, MacInnis RJ, Bickerstaffe A, et al. Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2016;25(2):359-365.
32. Mavaddat N, Pharoah PDP, Michailidou K, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015; 107(5) doi: 10.1093/jnci/djv036.
33. Vachon CM, Pankratz VS, Scott CG, et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst. 2015; 107(5) doi: 10.1093/jnci/dju397.
34. Mealiffe ME, Stokowski RP, Rhees BK, et al. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010;102(21):1618-1627.
35. Padhukasahasram B, Halperin E, Wessel J, et al. Presymptomatic risk assessment for chronic non-communicable diseases. PLoS One. 2010;5(12).
36. Campa D, Kaaks R, Le Marchand L, et al. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst. 2011;103(16):1252-1263.
37. Rudolph A, Chang-Claude J, Schmidt MK. Gene-environment interaction and risk of breast cancer. Br J Cancer. 2016;114(2):125-133.
38. Shieh Y, Hu D, Ma L, et al. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016;159(3):513-525.
39. Zheng W, Zhang B, Cai Q, et al. Common genetic determinants of breastcancer risk in East Asian women: A collaborative study of 23 637 breast cancer cases and 25 579 controls. Hum Mol Genet. 2013;22(12):2539-2550.
40. Fejerman L, Ahmadiyeh N, Hu D, et al. Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nat Commun. 2014;5:5260.
41. Sawyer S, Fejerman L. Genetic ancestry affects the predictive power of PRS in Latinas; Abstract 2804T. Presented at the 66th Annual Meeting of The American Society of Human Genetics; October 20, 2016; Vancouver, Canada.
42. Feng Y, Stram DO, Rhie SK, et al. A comprehensive examination of breast cancer risk loci in African American women. Hum Mol Genet. 2014;23(20): 5518-5526.
43. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243-2257.
44. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
45. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73(7):2025-2030.
46. Daly MB, Pilarski R, Berry M, et al. Genetic/familial high-risk assessment: Breast and ovarian, version 1.2017. NCCN Clinical Practice Guidelines in Oncology 2016.
47. Corso G, Intra M, Trentin C, et al. CDH1 germline mutations and hereditary lobular breast cancer. Fam Cancer. 2016;15(2):215-219.
48. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(∗)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55-59.
49. Lee AJ, Cunningham AP, Tischkowitz M, et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med. 2016; in press.
50. Schmidt MK, Hogervorst F, van Hien R, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2∗1100delC carriers. J Clin Oncol. 2016; 34(23):2750-2760.
51. Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderatepenetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016;13(9): 581-588.
52. Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Int Med. 2014;160(4):271-281.
53. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014;111(39):14205-14210.
54. Association for Molecular Pathology vs Myriad Genetics, 569 U.S. - (2013).
55. Bahcall O. Common variation and heritability estimates for breast, ovarian and prostate cancers. Nature iCogs Primers. 2016. http://www.nature.com/icogs/primer/common-variation-and-heritability-estimates-for-breast-ovar ian-and-prostate-cancers/. Accessed August 14, 2016.
56. Kerlikowske K, Zhu W, Hubbard RA, et al. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Int Med. 2013;173(9):807-816.
57. Moyer VA. Medications to decrease the risk for breast cancer in women: Recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(10):698-708.
58. Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Int Med. 2016;164(4):244-255.
59. Nelson HD, Pappas M, Cantor A. Harms of breast cancer screening: Systematic review to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Int Med. 2016;164(4):256-267.
60. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: A systematic review. JAMA. 2015;314(15):1615-1634.
61. Mandelblatt JS, Stout NK, Schechter CB. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. Ann Int Med. 2016;164(4):215-225.
62. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2013). http://www.seer.cancer.gov/pop data. Accessed June 12, 2016. Published 2016.
63. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427-437.
64. Ng AK, Garber JE, Diller LR, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013;31(18):2282-2288.
65. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317-1325.
66. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97(11):813-822.
67. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: Surveillance for breast cancer inwomen treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152(7):444-455; w144-w154.
68. Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32(21):2217-2223.
69. Ng A, Constine LS, Advani R, et al. ACR Appropriateness criteria: Follow-up of Hodgkin's lymphoma. Curr Probl Cancer. 2010;34(3):211-227.
70. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(5): 589-597.
71. Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013;60(4): 543-549.
72. Society of General Internal Medicine. Choosing wisely. http://www.choosing wisely.org/societies/society-of-general-internal-medicine/. Accessed August 11, 2016. Published 9/12/2013.
73. Lee SJ, Smith AS, Widera E, et al. Cancer screening. ePrognosis (online). 2015. http://cancerscreening.eprognosis.org/. Accessed July 11, 2016. Publication date unknown.
74. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1): a001008.
75. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-407.
76. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209-3215.
77. Wisdom: About the study (online). 2015. https://wisdom.secure.force.com/portal/WsdSiteStudy. Accessed June 9, 2016. Published 2015.
78. Oh SS, Galanter J, Thakur N, et al. Diversity in clinical and biomedical research: A promise yet to be fulfilled. PLoS Med. 2015;12(12):e1001918.
79. Kirsh VA, Chiarelli AM, Edwards SA, et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst. 2011;103(12):942-950.